Research progression of CD133 as a marker of cancer stem cells
- PMID: 20193104
- DOI: 10.5732/cjc.009.10587
Research progression of CD133 as a marker of cancer stem cells
Abstract
More and more evidences support the cancer stem cell (CSC) hypothesis which postulates that CSCs are responsible for tumor initiation metastasis recurrence and resistance to treatments. Therefore they are the targets of antitumor therapy. Sorting CSCs using specific surface markers is the premise of investigating their biological behaviors. Recently CD133 has been used extensively as a marker for the identification of stem cells from normal and cancerous tissues. Moreover CD133- positive (CD133+) tumor cells associate with the self-renewal differentiation potentials signal pathway drug-resistance recurrence and prognosis of tumors. Therefore CD133+ cells could be potential targets of antitumor therapy in the future.
Similar articles
-
CD133 as a marker for cancer stem cells: progresses and concerns.Stem Cells Dev. 2009 Oct;18(8):1127-34. doi: 10.1089/scd.2008.0338. Stem Cells Dev. 2009. PMID: 19409053 Review.
-
The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.J Mol Med (Berl). 2008 Sep;86(9):1025-32. doi: 10.1007/s00109-008-0357-8. Epub 2008 Jun 6. J Mol Med (Berl). 2008. PMID: 18535813 Free PMC article. Review.
-
Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.Oncol Rep. 2012 Oct;28(4):1301-8. doi: 10.3892/or.2012.1951. Epub 2012 Aug 6. Oncol Rep. 2012. PMID: 22895640 Free PMC article.
-
In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.PLoS One. 2008;3(10):e3544. doi: 10.1371/journal.pone.0003544. Epub 2008 Oct 28. PLoS One. 2008. PMID: 18958156 Free PMC article.
-
Targeting CD133 antigen in cancer.Expert Opin Ther Targets. 2009 Jul;13(7):823-37. doi: 10.1517/14728220903005616. Expert Opin Ther Targets. 2009. PMID: 19530986 Review.
Cited by
-
APEX1 predicts poor prognosis of gallbladder cancer and affects biological properties of CD133+ GBC-SD cells via upregulating Jagged1.J Cancer. 2023 May 15;14(8):1443-1457. doi: 10.7150/jca.83356. eCollection 2023. J Cancer. 2023. PMID: 37283798 Free PMC article.
-
Evaluation of CD133 and CD56/NCAM expression in Wilms tumor and their association with prognostic factors.Iran J Basic Med Sci. 2020 Jul;23(7):853-857. doi: 10.22038/ijbms.2020.41468.9804. Iran J Basic Med Sci. 2020. PMID: 32774805 Free PMC article.
-
CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells.Radiother Oncol. 2014 Mar;110(3):538-45. doi: 10.1016/j.radonc.2013.10.040. Epub 2014 Jan 16. Radiother Oncol. 2014. PMID: 24440048 Free PMC article.
-
Sox12 Is a Cancer Stem-Like Cell Marker in Hepatocellular Carcinoma.Mol Cells. 2017 Nov 30;40(11):847-854. doi: 10.14348/molcells.2017.0129. Epub 2017 Nov 10. Mol Cells. 2017. PMID: 29127951 Free PMC article.
-
Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes.PLoS One. 2014 Feb 18;9(2):e88706. doi: 10.1371/journal.pone.0088706. eCollection 2014. PLoS One. 2014. PMID: 24558415 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials